Progress in research on urine proteomics of kidney diseases

doi:10.3877/cma.j.issn.2095-3216.2017.03.008

Abstract

Abstract:

At present, the invasive pathological examination is required for diagnosis of the vast majority of kidney diseases, including autoimmune kidney diseases and renal tumors. As a biological sample that can be collected by non-invasive and repeatable methods, the urinary proteins, among which 70% are from the urinary system itself, and 30% from the blood through hemofiltration, are the best sources to search for biological markers of the urinary system diseases. Since the concept of "proteome" was raised in 1994, proteomics research has developed rapidly. The continuous improvement in proteomics technology and bioinformatics analysis tools in the 20th century has promoted the progress of proteomics research. This review focused on the development history of urinary proteomics, and the most recent progress of research on proteomic techniques as well as urine proteomics of different renal diseases.

Key words: Kidney disease, Proteomics, Urine

Shuqiang Wang, Xiaodong Geng, Di Wu. Progress in research on urine proteomics of kidney diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2017, 06(03): 132-137.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2017.03.008

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2017/V06/I03/132

References 54

[1]	Wasinger VC, Cordwell SJ, Cerpa-Poljak A, et al. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium [J]. Electrophoresis, 1995, 16(7): 1090-1094.
[2]	Witzmann F, Clack J, Fultz C, et al. Two-dimensional electrophoretic mapping of hepatic and renal stress proteins [J]. Electrophoresis, 1995, 16(3): 451-459.
[3]	Marshall T, Williams K. Two-dimensional electrophoresis of human urinary proteins following concentration by dye precipitation [J]. Electrophoresis, 1996, 17(7): 1265-1272.
[4]	Heine G, Raida M, Forssman WG. Mapping of peptides and protein fragments in human urine using liquid chromatography-mass spectrometry [J]. J Chromatogr A, 1997, 776(1): 117-124.
[5]	Sarto C, Marocchi A, Sanchez JC, et al. Renal cell carcinoma and normal kidney protein expression [J]. Electrophoresis, 1997, 18(3-4): 599-604.
[6]	Thongboonkerd V. Proteomics in nephrology: current status and future directions [J]. Am J Nephrol, 2004, 24(3): 360-378.
[7]	Shen Y, Zhao R, Berger SJ, et al. High-efficiency nanoscale liquid chromatography coupled on-line with mass spectrometry using nanoelectrospray ionization for proteomics [J]. Anal Chem, 2002, 74(16): 4235-4249.
[8]	Santucci L, Candiano G, Petretto A, et al. From hundreds to thousands: widening the normal human urinome [J]. J Proteomics, 2015, 112(1): 53-62.
[9]	Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics [J]. Mol Cell Proteomics, 2008, 7(10): 1850-1862.
[10]	Dihazi H. The urinary proteomics: a tool to discover new and potent biomarkers for kidney damage [J]. Ejifcc, 2009, 20(1): 83-82.
[11]	Gonzalez-Buitrago JM, Ferreira LLorenzo I. Urinary proteomics [J]. Clin Chim Acta, 2007, 375(1-2): 49-56.
[12]	Liu Z, Yuan Z, Zhao Q. SELDI-TOF-MS proteomic profiling of serum, urine, and amniotic fluid in neural tube defects [J]. PLoS One, 2014, 9(7): e103276.
[13]	Janech MG, Raymond JR, Arthur JM. Proteomics in renal research [J]. Am J Physiol Renal Physiol, 2007, 292(2): F501-F512.
[14]	Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary proteome analysis and biomarker discovery [J]. J Am Soc Nephrol, 2007, 18(4): 1057-1071.
[15]	Maeland Nilsen M, Uleberg KE, Janssen EA, et al. From SELDI-TOF MS to protein identification by on-chip elution [J]. J Proteomics, 2011, 74(12): 2995-2998.
[16]	Ibanez C, Simo C, Garcia-Canas V, et al. Metabolomics, peptidomics and proteomics applications of capillary electrophoresis-mass spectrometry in foodomics: a review [J]. Anal Chim Acta, 2013, 802: 1-13.
[17]	Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future [J]. J Proteome Res, 2007, 6(12): 4549-4555.
[18]	Adachi J, Kumar C, Zhang Y, et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins [J]. Genome Biol, 2006, 7(9): R80.
[19]	Husi H, Stephens N, Cronshaw A, et al. Proteomic analysis of urinary upper gastrointestinal cancer markers [J]. Proteomics Clin Appl, 2011, 5(5-6): 289-299.
[20]	Wasinger VC, Zeng M, Yau Y. Current status and advances in quantitative proteomic mass spectrometry [J]. Int J Proteomics, 2013, 2013: 180605.
[21]	Davis MT, Spahr CS, McGinley MD, et al. Towards defining the urinary proteome using liquid chromatography-tandem mass spectrometry. II. Limitations of complex mixture analyses [J]. Proteomics, 2001, 1(1): 108-117.
[22]	Khan A, Packer NH. Simple urinary sample preparation for proteomic analysis [J]. J Proteome Res, 2006, 5(10): 2824-2838.
[23]	Ngai HH, Sit WH, Jiang PP, et al. Serial changes in urinary proteome profile of membranous nephropathy: implications for pathophysiology and biomarker discovery [J]. J Proteome Res, 2006, 5(11): 3038-3047.
[24]	Kentsis A, Monigatti F, Dorff K, et al. Urine proteomics for profiling of human disease using high accuracy mass spectrometry [J]. Proteomics Clin Appl, 2009, 3(9): 1052-1061.
[25]	Li QR, Fan KX, Li RX, et al. A comprehensive and non-prefractionation on the protein level approach for the human urinary proteome: touching phosphorylation in urine [J]. Rapid Commun Mass Spectrom, 2010, 24(6): 823-832.
[26]	Nagaraj N, Mann M. Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome [J]. J Proteome Res, 2011, 10(2): 637-645.
[27]	Zerefos PG, Aivaliotis M, Baumann M, et al. Analysis of the urine proteome via a combination of multi-dimensional approaches [J]. Proteomics, 2012, 12(3): 391-400.
[28]	Farrah T, Deutsch EW, Omenn GS, et al. State of the human proteome in 2013 as viewed through PeptideAtlas: comparing the kidney, urine, and plasma proteomes for the biology- and disease-driven Human Proteome Project [J]. J Proteome Res, 2014, 13(1): 60-75.
[29]	Santucci L, Bruschi M, Candiano G, et al. Urine proteome biomarkers in kidney diseases. I. Limits, perspectives, and first focus on normal urine [J]. Biomark Insights, 2016, 11: 41-48.
[30]	Di Meo A, Batruch I, Yousef AG, et al. An integrated proteomic and peptidomic assessment of the normal human urinome [J]. Clin Chem Lab Med, 2017, 55(2): 237-247.
[31]	Bouatra S, Aziat F, Mandal R, et al. The human urine metabolome [J]. PLoS One, 2013, 8(9): e73076.
[32]	Julian BA, Wittke S, Novak J, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases [J]. Electrophoresis, 2007, 28(23): 4469-4483.
[33]	Rocchetti MT, Papale M, d'Apollo AM, et al. Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy [J]. Clin J Am Soc Nephrol, 2013, 8(7): 1115-1125.
[34]	Zhao S, Li R, Cai X, et al. The application of SILAC mouse in human body fluid proteomics analysis reveals protein patterns associated with IgA nephropathy [J]. Evid Based Complement Alternat Med, 2013, 2013: 275390.
[35]	Kalantari S, Rutishauser D, Samavat S, et al. Urinary prognostic biomarkers and classification of IgA nephropathy by high resolution mass spectrometry coupled with liquid chromatography [J]. PLoS One, 2013, 8(12): e80830.
[36]	Mucha K, Bakun M, Jazwiec R, et al. Complement components, proteolysisrelated, and cell communicationrelated proteins detected in urine proteomics are associated with IgA nephropathy [J]. Pol Arch Med Wewn, 2014, 124(7-8): 380-386.
[37]	Rood IM, Merchant ML, Wilkey DW, et al. Increased expression of lysosome membrane protein 2 in glomeruli of patients with idiopathic membranous nephropathy [J]. Proteomics, 2015, 15(21): 3722-3730.
[38]	Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy [J]. N Engl J Med, 2009, 361(1): 11-21.
[39]	Suzuki M, Wiers K, Brooks EB, et al. Initial validation of a novel protein biomarker panel for active pediatric lupus nephritis [J]. Pediatr Res, 2009, 65(5): 530-536.
[40]	Aggarwal A, Gupta R, Negi VS, et al. Urinary haptoglobin, alpha-1 anti-chymotrypsin and retinol binding protein identified by proteomics as potential biomarkers for lupus nephritis [J]. Clin Exp Immunol, 2017, 188(2): 254-262.
[41]	Soldatos G, Cooper ME. Diabetic nephropathy: important pathophysiologic mechanisms [J]. Diabetes Res Clin Pract, 2008, 82(Suppl 1): S75-S79.
[42]	Zurbig P, Jerums G, Hovind P, et al. Urinary proteomics for early diagnosis in diabetic nephropathy [J]. Diabetes, 2012, 61(12): 3304-3313.
[43]	Zubiri I, Posada-Ayala M, Sanz-Maroto A, et al. Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis [J]. J Proteomics, 2014, 96: 92-102.
[44]	Lewandowicz A, Bakun M, Kohutnicki R, et al. Changes in urine proteome accompanying diabetic nephropathy progression [J]. Pol Arch Med Wewn, 2015, 125(1-2): 27-38.
[45]	Marikanty RK, Gupta MK, Cherukuvada SV, et al. Identification of urinary proteins potentially associated with diabetic kidney disease [J]. Indian J Nephrol, 2016, 26(6): 434-445.
[46]	Nguyen MT, Ross GF, Dent CL, et al. Early prediction of acute renal injury using urinary proteomics [J]. Am J Nephrol, 2005, 25(4): 318-326.
[47]	Metzger J, Kirsch T, Schiffer E, et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury [J]. Kidney Int, 2010, 78(12): 1252-1262.
[48]	Aregger F, Uehlinger DE, Witowski J, et al. Identification of IGFBP-7 by urinary proteomics as a novel prognostic marker in early acute kidney injury [J]. Kidney Int, 2014, 85(4): 909-919.
[49]	Bosso N, Chinello C, Picozzi SC, et al. Human urine biomarkers of renal cell carcinoma evaluated by ClinProt [J]. Proteomics Clin Appl, 2008, 2(7-8): 1036-1046.
[50]	Raimondo F, Morosi L, Corbetta S, et al. Differential protein profiling of renal cell carcinoma urinary exosomes [J]. Mol Biosyst, 2013, 9(6): 1220-1233.
[51]	Sandim V, Pereira Dde A, Kalume DE, et al. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma [J]. Urol Oncol, 2016, 34(1): 5.e11-25.
[52]	Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine [J]. Proc Natl Acad Sci USA, 2004, 101(36): 13368-13373.
[53]	Moon PG, You S, Lee JE, et al. Urinary exosomes and proteomics [J]. Mass Spectrom Rev, 2011, 30(6): 1185-1202.
[54]	Gonzales PA, Pisitkun T, Hoffert JD, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes [J]. J Am Soc Nephrol, 2009, 20(2): 363-379.

Please choose a citation manager

Content to export